自引率: 暂无数据
被引量: 2351
通过率: 暂无数据
审稿周期: 暂无数据
版面费用: 暂无数据
国人发稿量: 暂无数据
投稿须知/期刊简介:
Trends in Cancer is a new member of the Trends review journals, offering concise and engaging expert commentary articles that address key frontline research topics and cutting-edge advances in the rapidly changing field of cancer discovery and medicine. The journal provides a unique platform for multidisciplinary information, discussion and education that is valuable for scientists, clinicians, and policy makers, as well as patients & advocates. The latest opportunities, challenges and potential impact of basic, translational and clinical findings, industry R&D, technology and innovation, ethics, or cancer policy and funding are equally presented and debated in an authoritative but reader-friendly format. Critical issues to be covered in the journal include: Adult and Pediatric Cancers; Personalized Medicine; Tumor Microenvironment, Resistance and Metastasis; Immunotherapy; Metabolism; Genetics and Epigenetics; Diagnostics, Biomarkers and Treatment; Epidemiology and Cancer Prevention; Cancer related Ethics, Policy and Funding Initiatives.
期刊描述简介:
Trends in Cancer is a new member of the Trends review journals, offering concise and engaging expert commentary articles that address key frontline research topics and cutting-edge advances in the rapidly changing field of cancer discovery and medicine. The journal provides a unique platform for multidisciplinary information, discussion and education that is valuable for scientists, clinicians, and policy makers, as well as patients & advocates. The latest opportunities, challenges and potential impact of basic, translational and clinical findings, industry R&D, technology and innovation, ethics, or cancer policy and funding are equally presented and debated in an authoritative but reader-friendly format. Critical issues to be covered in the journal include: Adult and Pediatric Cancers; Personalized Medicine; Tumor Microenvironment, Resistance and Metastasis; Immunotherapy; Metabolism; Genetics and Epigenetics; Diagnostics, Biomarkers and Treatment; Epidemiology and Cancer Prevention; Cancer related Ethics, Policy and Funding Initiatives.
-
Scaling data toward pan-cancer foundation models.
被引量：1 发表：1970
-
Epigenetic control of immunoevasion in cancer stem cells.
Cancer stem cells (CSCs) are a poorly differentiated population of malignant cells that (at least in some neoplasms) is responsible for tumor progression, resistance to therapy, and disease relapse. According to a widely accepted model, all stages of cancer progression involve the ability of neoplastic cells to evade recognition or elimination by the host immune system. In line with this notion, CSCs are not only able to cope with environmental and therapy-elicited stress better than their more differentiated counterparts but also appear to better evade tumor-targeting immune responses. We summarize epigenetic modifications of DNA and histones through which CSCs evade immune recognition or elimination, and propose that such alterations constitute promising therapeutic targets to increase the sensitivity of some malignancies to immunotherapy.
被引量：- 发表：1970
-
Mechanisms governing lineage plasticity and metabolic reprogramming in cancer.
Dynamic alterations in cellular phenotypes during cancer progression are attributed to a phenomenon known as 'lineage plasticity'. This process is associated with therapeutic resistance and involves concurrent shifts in metabolic states that facilitate adaptation to various stressors inherent in malignant growth. Certain metabolites also serve as synthetic reservoirs for chromatin modification, thus linking metabolic states with epigenetic regulation. There remains a critical need to understand the mechanisms that converge on lineage plasticity and metabolic reprogramming to prevent the emergence of lethal disease. This review attempts to offer an overview of our current understanding of the interplay between metabolic reprogramming and lineage plasticity in the context of cancer, highlighting the intersecting drivers of cancer hallmarks, with an emphasis on solid tumors.
被引量：- 发表：1970
-
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells.
Many tumors prefer to metastasize to bone, but the underlying mechanisms remain elusive. The human skeletal system has unique physical properties, that are distinct from other organs, which play a key role in directing the behavior of tumor cells within bone. Understanding the physical journey of tumor cells within bone is crucial. In this review we discuss bone metastasis in the context of how physical cues in the bone vasculature and bone marrow niche regulate the fate of tumor cells. Our objective is to inspire innovative diagnostic and therapeutic approaches for bone metastasis from a mechanobiological perspective.
被引量：- 发表：1970
-
Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights.
The evolution of antitumor therapies has significantly improved cancer prognosis but has concurrently resulted in cardiovascular toxicities. Understanding the biological mechanisms behind these toxicities is crucial for effective management. Immunotherapy-related cardiovascular toxicities are primarily mediated by immune cells and secreted cytokines. Chemotherapy may cause cardiovascular damage through autophagy disruption and mitochondrial dysfunction. Targeted therapies can induce toxicity through endothelin-1 (ET-1) production and cardiac signaling disruption. Radiotherapy may lead to cardiomyopathy and myocardial fibrosis by affecting endothelial cells, triggering inflammatory responses and accelerating atherosclerosis. This review provides insights into these mechanisms and strategies, aiming to enhance the clinical prevention and treatment of cardiovascular toxicities.
被引量：- 发表：1970
